Soluble interleukin-2 receptor serum level is a useful marker of hidradenitis suppurativa clinical staging

Biomarkers

Volumn 14, Issue 6, 2009, Pages 432-437

  Matusiak, Łukasz ^a   Bieniek, Andrzej ^a   Szepietowski, Jacek C ^a,b  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

Author keywords

Acne inversa; CRP; ESR; Hidradenitis suppurativa; Leukocytosis; SIL 2R; WBC

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 2 RECEPTOR;

ADOLESCENT; ADULT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE CLASSIFICATION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; LABORATORY TEST; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; SCORING SYSTEM; STATISTICAL ANALYSIS; SUPPURATIVE HIDRADENITIS;

AGED; BIOLOGICAL MARKERS; FEMALE; HIDRADENITIS SUPPURATIVA; HUMANS; LABORATORY TECHNIQUES AND PROCEDURES; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-2; SENSITIVITY AND SPECIFICITY;

EID: 70849089194     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.1080/13547500903075218     Document Type: Article

References (43)

1. Alikhan A, Lynch PJ, Eisen DB. (2009). Hidradenitis suppurativa: a comprehensive review. J Am Acad Dermatol 60:539-561
2. Betti R, Rosti A, Lodi A. Bencini PL, Paparelli S, Gazzola GB, Cori P, Moroni GA, Crosti C. (1991). Effect of UVB plus tar therapy on serum levels of interleukin-2 receptors in patients with psoriasis. Clin Exp Dermatol 16:364-366
3. Canoui-Poitrine F, Revuz JE, Wolkenstein P, Viallette C, Gabison G, Pouget F, Poli F, Faye O, Bastuji-Garin S. (2009). Clinical characteristics of a series of 302 French patients with hidradenitis suppurativa, with an analysis of factors associated with disease severity. J Am Acad Dermatol 28: (Epub ahead of print).
4. Chodorowska G, Czelej D, Niewiedzio? M. (2003). Interleukin-2 and its soluble receptor in selected drug-induced cutaneous reactions. Ann Univ Mariae Curie Sklodowska 58:7-13.
5. Colver GB, Symons JA, Duff GW. (1989). Soluble interleukin 2 receptor in atopic eczema. BMJ 298:1426-1428
6. De Rie MA, Zonneveld IM, Witkamp L, Van Lier RA, Out TA, Bos JD. (1996). Soluble interleukin-2 receptor (sIL-2R) is a marker of disease activity in psoriasis: a comparison of sIL-2R, sCD27, sCD4, sCD8 and sICAM-1. Acta Derm Venereol 76:357-360
7. Elias AN, Goodman MM, Rohan MK. (1993). Effect of propylthiouracil and methimazole on serum levels of interleukin-2 receptors in patients with psoriasis. Int J Dermatol 32:537-540
8. Elkayam O, Yaron I, Shirazi I, Yaron M, Caspi D. (2000). Serum levels of IL-10, IL-6, IL-1ra, and sIL-2R in patients with psoriatic arthritis. Rheumatol Int 19:101-105 (Pubitemid 30189841)
9. Gebhardt M, Wenzel HC, Hipler UC, Herrmann D, Wollina U. (1997). Monitoring of serologic immune parameters in inflammatory skin diseases. Allergy 52:1087-1094
10. Giamarellos-Bourboulis EJ, Antonopoulou A, Petropoulou C, Mouktaroudi M, Spyridaki E, Baziaka F, Pelekanou A, Giamarellou H, Stavrianeas NG. (2007). Altered innate and adaptive immune responses in patients with hidradenitis suppurativa. Br J Dermatol 156:51-56
11. Halmerbauer G, Frischer T, Koller DY. (1997). Monitoring of disease activity by measurement of inflammatory markers in atopic dermatitis in childhood. Allergy 52:765-769
12. Hurley H. (1989). Dermatologic Surgery, Principles And Practice. New York: Marcel Dekker.
13. Itoh M, Goto Y, Ohta Y, Goto Y, Ohashi H. (1998). Relations between surface expression of the interleukin-2 receptor and release of the soluble form of the receptor in cultured mononuclear cells from patients with rheumatoid arthritis or systemic lupus erythematosus. Clin Rheumatol 17:26-30.
14. Jemec GB. (2004). Medical treatment of hidradenitis suppurativa. Expert Opin Pharmacother 5:1767-1770
15. Kägi MK, Joller-Jemelka H, Wüthrich B. (1992). Correlation of eosinophils, eosinophil cationic protein and soluble interleukin- 2 receptor with the clinical activity of atopic dermatitis. Dermatology 185:88-92.
16. Kami M, Matsumura T, Tanaka Y, Mikami Y, Miyakoshi S, Ueyama J, Morinaga S, Mori S, Machida U, Kanda Y, Chiba S, Sakamaki H, Hirai H, Muto Y. (2000). Serum levels of soluble interleukin-2 receptor after bone marrow transplantation: a true marker of acute graft-versus-host disease. Leuk Lymphoma 38:533-540
17. Kapp A, Piskorski A, Schöpf E. (1988). Elevated levels of interleukin 2 receptor in sera of patients with atopic dermatitis and psoriasis. Br J Dermatol 119:707-710
18. Karvonen SL, Räsänen L, Soppi E. Hyöty H, Lehtinen M, Reunala T. (1995). Increased chemiluminescence of whole blood and normal T-lymphocyte subsets in severe nodular acne and acne fulminans. Acta Derm Venereol 75:1-5.
19. Kemmett D, Symons JA, Colver GB, Duff GW. (1990). Serum-soluble interleukin 2 receptor in psoriasis. Failure to reflect clinical improvement. Acta Derm Venereol 70:264-266
20. Korobowicz A. (2006). [Biology of tumor necrosis factor type alpha (TNF-alpha)]. Pol Merkur Lekarski 21:358-361
21. Kurzen H, Kurokawa I, Jemec GB, Emtestam L, Sellheyer K, Giamarellos-Bourboulis EJ, Nagy I, Bechara FG, Sartorius K, Lapins J, Krahl D, Altmeyer P, Revuz J, Zouboulis CC. (2008). What causes hidradenitis suppurativa? Exp Dermatol 17:455-456
22. Lapins J, Asman B, Gustafsson A, Bergström K, Emtestam L. (2001). Neutrophil-related host response in hidradenitis suppurativa: a pilot study in patients with inactive disease. Acta Derm Venereol 81:96-99
23. Leonardi S, Marchese G, Rotolo N, Miraglia Del Giudice M, La Rosa M. 2004. Cyclosporin is safe and effective in severe atopic dermatitis of childhood. Report of three cases. Minerva Pediatr 56:231-237
24. Matsumoto T, Furukawa A, Sumiyoshi Y, Akiyama KY, Kanayama HO, Kagawa S. (1998). Serum levels of soluble interleukin-2 receptor in renal cell carcinoma. Urology 51:145-149
25. Nakata B, Chung KH, Kato Y, Yamashita Y, Inui A, Arimoto Y, Maeda K, Onoda N, Sawada T, Sowa M. (1998). Serum soluble interleukin-2 receptor level as a prognostic indicator in gastric cancer. Br J Cancer 77:1820-1824
26. Niitsu N, Iijima K, Chizuka A. (2001). A high serum-soluble interleukin- 2 receptor level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma. Eur J Haematol 66:24-30.
27. O'Loughlin S, Woods R, Kirke PN, Shanahan F, Byrne A, Drury MI. (1988). Hidradenitis suppurativa. Glucose tolerance, clinical, microbiologic, and immunologic features and HLA frequencies in 27 patients. Arch Dermatol 124:1043-1046
28. Plewig G, Steger M. (1989). Acne inversa. In: Marks R, Plewig G, editors. Acne and Related Disorders. London: Martin Dunitz Ltd. p. 345-347
29. Poli F, Jemec GB, Revuz J. (2006). Clinical presentation. In: Jemec GB, Revuz J, Leyden J, editors. Hidradenitis Suppurativa. Heidelberg: Springer. p. 11-24.
30. Revuz J. (2007). Modifications et mode d'emploi du score de Sartorius pour évaluer la gravité de l'hidradénite suppurée. Ann Dermatol Venereol 134:173-180
31. Rubin LA, Kurman CC, Fritz ME, Biddison WE, Boutin B, Yarchoan R, Nelson DL. (1985). Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J Immunol 135:3172-3177
32. Sartorius K, Lapins J, Emtestam L, Jemec GB. (2003). Suggestions for uniform outcome variables when reporting treatment effects in hidradenitis suppurativa. Br J Dermatol 149:211-213
33. Sellheyer K, Krahl D. (2005). 'Hidradenitis suppurativa' is acne inversa! An appeal to (finally) abandon a misnomer. Int J Dermatol 44:535-540
34. Serhat Inaloz H, Ozturk S, Akcali C, Kirtak N, Tarakcioglu M. (2008). Low-dose and short-term cyclosporine treatment in patients with chronic idiopathic urticaria: a clinical and immunological evaluation. J Dermatol 35:276-282
35. Shohat M, Mimouni D, Ben-Amitai D, Sredni B, Sredni D, Shohat B, David M. (2005). In vitro cytokine profile in childhood alopecia areata and the immunomodulatory effects of AS-101. Clin Exp Dermatol 30:432-434
36. Spadaro A, Riccieri V, Benfari G, Scillone M, Taccari E. (2001). Soluble interleukin-2 receptor in Sjögren's syndrome: relation to main serum immunological and immunohistochemical parameters. Clin Rheumatol 20:319-323
37. Suenaga Y, Yasuda M, Yamamoto M. Nonaka S, Wada T, Shiokawa S, Nobunaga M. (1998). Serum interleukin-2 receptor for the early diagnosis of rheumatoid arthritis. Clin Rheumatol 17:311-317
38. Tartour E, Mosseri V, Jouffroy T, Deneux L, Jaulerry C, Brunin F, Fridman WH, Rodriguez J. (2001). Serum soluble interleukin-2 receptor concentrations as an independent prognostic marker in head and neck cancer. Lancet 357:1263-1264
39. Valsecchi R, Imberti G, Martino D, Cainelli T. (1992). Alopecia areata and interleukin-2 receptor. Dermatology 184:126-128
40. von der Werth JM, Jemec GB. (2001). Morbidity in patients with hidradenitis suppurativa. Br J Dermatol 144:809-813
41. Vonderheid EC, Zhang Q, Lessin SR, Polansky M, Abrams JT, Bigler RD, Wasik MA. (1998). Use of serum soluble interleukin-2 receptor levels to monitor the progression of cutaneous T-cell lymphoma. J Am Acad Dermatol 38:207-220
42. Wortsman X, Revuz J, Jemec GB. (2009). Lymph nodes in hidradenitis suppurativa. Dermatology (Epub ahead of print).
43. Zillikens D, Ambach A, Zentner A. Dummer R, Schüssler M, Burg G, Bröcker EB. (1993). Evidence for cell-mediated immune mechanisms in the pathology of pemphigus. Br J Dermatol 128:636-643